glp-1 obesity drug updates The FDA approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication GLP-1 analogs, new trend in

Description

Previous experiments have found that exendin-4 could reduce the pain-induced neuro-inflammatory response through the GLP-1R pathway, thereby promoting the recovery of cognitive function in mice (100)

Saxenda may be worth discussing if: You did not tolerate semaglutide or tirzepatide well, and liraglutide offers a different side-effect profile for you specifically You are between 12 and 17 years old and your clinician recommends liraglutide over semaglutide in your case You prefer a daily injection routine over a weekly one for habit or medical reasons You want one of the longest-established track records in the class with over a decade of real-world safety data Mounjaro vs Wegovy: what the head-to-head data actually says For years, comparing Mounjaro and Wegovy meant comparing separate trials in separate patient populations with different designs

While this single case cannot establish a pattern, it raises questions about whether compounded formulations might carry different risk profiles due to variations in purity, concentration, or additional ingredients